Induction and escalation therapies in multiple sclerosis.

Area of Science:

• Neuroimmunology
• Neurology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic central nervous system demyelinating disease.
• Current pharmacological therapies include symptomatic treatments, relapse management, and disease-modifying drugs (DMDs).
• Two primary therapeutic strategies are escalation and induction therapy.

Purpose of the Study:

• To review current pharmacological approaches for multiple sclerosis treatment.
• To discuss the principles and applications of escalation and induction therapy.
• To highlight the challenges and future directions in MS treatment personalization.

Main Methods:

• Review of existing literature on MS pharmacological therapies.
• Analysis of escalation therapy using first-line and second-line DMDs.
• Evaluation of induction therapy involving early immunosuppression followed by maintenance.

Main Results:

• Escalation therapy starts with first-line DMDs, switching to second-line if ineffective.
• Induction therapy uses potent immunosuppressants early, followed by maintenance.
• While effective for aggressive MS, induction therapy's safety profile limits its universal application.

Conclusions:

• The choice between escalation and induction therapy depends on MS aggressiveness and patient factors.
• Individualized treatment strategies are needed, considering clinical, radiological, and biomarker data.
• Future research should focus on identifying high-risk patients and stratifying safety profiles for personalized MS management.